Cover Image
Market Research Report
Product code 
1068135

Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Published: | Transparency Market Research | 151 Pages | Delivery time: 1-2 business days

Price

Back to Top
Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028
Published: February 2, 2022
Transparency Market Research
Content info: 151 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Scope of the Report

TMR's report on the global pharmacovigilance market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2028. The report provides revenue of the global pharmacovigilance market for the period 2017-2028, considering 2020 as the base year and 2028 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global pharmacovigilance market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players' literature, annual reports, press releases, and relevant documents to understand the global pharmacovigilance market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global pharmacovigilance market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global pharmacovigilance market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global pharmacovigilance market.

The report delves into the competition landscape of the global pharmacovigilance market. Key players operating in the global pharmacovigilance market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global pharmacovigilance market that have been profiled in this report.

Key Questions Answered:

  • What is the scope of growth of phase of drug development companies in the global pharmacovigilance market?
  • What will be the Y-o-Y growth of the global pharmacovigilance market between 2019 and 2027?
  • What is the influence of changing trends in technologies on the global pharmacovigilance market?
  • Which region is likely to be the most profitable market for pharmacovigilance?
  • Which factors are anticipated to hamper the growth of the global pharmacovigilance market during the forecast period?
  • Which are the leading companies in the global pharmacovigilance market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global pharmacovigilance market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global pharmacovigilance market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR's study on the pharmacovigilance market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the pharmacovigilance market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global pharmacovigilance market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR's estimates on future prospects of the global pharmacovigilance market more reliably and accurately.

Product Code: TMRGL1729

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pharmacovigilance Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Market Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Pharmacovigilance Market Analysis and Forecast, 2017-2028
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. COVID-19 Impact on the Pharmacovigilance Market
  • 5.2. Technological Advancements (big data analytics, cloud-based database, automation)
  • 5.3. Drugs Regulatory Framework of Pharmacovigilance Market
  • 5.4. Pharmacovigilance Market: Value Chain Analysis
  • 5.5. Pharmacovigilance Market: Porter's Five Forces Analysis
  • 5.6. Overview of Drugs Adverse Effects

6. Global Pharmacovigilance Market Analysis and Forecast, by Phase of Drug Development

  • 6.1. Introduction & Definition
    • 6.1.1. Key Findings / Developments
  • 6.2. Global Pharmacovigilance Market Value Forecast, by Phase of Drug Development, 2017-2028
    • 6.2.1. Preclinical Studies
    • 6.2.2. Phase I
    • 6.2.3. Phase II
    • 6.2.4. Phase III
    • 6.2.5. Phase IV or Post Marketing Surveillance
  • 6.3. Global Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028

7. Global Pharmacovigilance Market Analysis and Forecast, by Type of Method

  • 7.1. Introduction & Definition
    • 7.1.1. Key Findings / Developments
  • 7.2. Global Pharmacovigilance Market Value Forecast, by Type of Method, 2017-2027
    • 7.2.1. Spontaneous Reporting
    • 7.2.2. Intensified ADR Reporting
    • 7.2.3. Targeted Spontaneous Reporting
    • 7.2.4. Cohort Event Monitoring
    • 7.2.5. EHR Mining
  • 7.3. Global Pharmacovigilance Market Attractiveness Analysis, by Type of Method,2021-2028

8. Global Pharmacovigilance Market Analysis and Forecast, by Type of Service

  • 8.1. Introduction & Definition
    • 8.1.1. Key Findings / Developments
  • 8.2. Global Pharmacovigilance Market Value Forecast, by Type of Service, 2017-2027
    • 8.2.1. In-house
    • 8.2.2. Contract Outsourcing
  • 8.3. Global Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

9. Global Pharmacovigilance Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Global Pharmacovigilance Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. North America Pharmacovigilance Market Attractiveness Analysis, by Region, 2021-2028

10. North America Pharmacovigilance Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017-2027
    • 10.2.1. Preclinical Studies
    • 10.2.2. Phase I
    • 10.2.3. Phase II
    • 10.2.4. Phase III
    • 10.2.5. Phase IV or Post Marketing Surveillance
  • 10.3. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017-2027
    • 10.3.1. Spontaneous Reporting
    • 10.3.2. Intensified ADR Reporting
    • 10.3.3. Targeted Spontaneous Reporting
    • 10.3.4. Cohort Event Monitoring
    • 10.3.5. EHR Mining Others
  • 10.4. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017-2027
    • 10.4.1. In-house
    • 10.4.2. Contract Outsourcing
  • 10.5. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Country, 2017-2027
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. North America Pharmacovigilance Market Attractiveness Analysis, 2021-2028
    • 10.6.1. By Phase of Drug Development
    • 10.6.2. By Type of Method
    • 10.6.3. By Type of Service
    • 10.6.4. By Country

11. Europe Pharmacovigilance Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017-2027
    • 11.2.1. Preclinical Studies
    • 11.2.2. Phase I
    • 11.2.3. Phase II
    • 11.2.4. Phase III
    • 11.2.5. Phase IV or Post Marketing Surveillance
  • 11.3. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017-2027
    • 11.3.1. Spontaneous Reporting
    • 11.3.2. Intensified ADR Reporting
    • 11.3.3. Targeted Spontaneous Reporting
    • 11.3.4. Cohort Event Monitoring
    • 11.3.5. EHR Mining
  • 11.4. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017-2027
    • 11.4.1. In-house
    • 11.4.2. Contract Outsourcing
  • 11.5. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Europe Pharmacovigilance Market Attractiveness Analysis, 2021-2028
    • 11.6.1. By Phase of Drug Development
    • 11.6.2. By Type of Method
    • 11.6.3. By Type of Service
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Pharmacovigilance Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017-2027
    • 12.2.1. Preclinical Studies
    • 12.2.2. Phase I
    • 12.2.3. Phase II
    • 12.2.4. Phase III
    • 12.2.5. Phase IV or Post Marketing Surveillance
  • 12.3. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017-2027
    • 12.3.1. Spontaneous Reporting
    • 12.3.2. Intensified ADR Reporting
    • 12.3.3. Targeted Spontaneous Reporting
    • 12.3.4. Cohort Event Monitoring
    • 12.3.5. EHR Mining
  • 12.4. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017-2027
    • 12.4.1. In-house
    • 12.4.2. Contract Outsourcing
  • 12.5. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Asia Pacific Pharmacovigilance Market Attractiveness Analysis, 2021-2028
    • 12.6.1. By Phase of Drug Development
    • 12.6.2. By Type of Method
    • 12.6.3. By Type of Service
    • 12.6.4. By Country/Sub-region

13. Latin America Pharmacovigilance Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017-2027
    • 13.2.1. Preclinical Studies
    • 13.2.2. Phase I
    • 13.2.3. Phase II
    • 13.2.4. Phase III
    • 13.2.5. Phase IV or Post Marketing Surveillance
  • 13.3. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017-2027
    • 13.3.1. Spontaneous Reporting
    • 13.3.2. Intensified ADR Reporting
    • 13.3.3. Targeted Spontaneous Reporting
    • 13.3.4. Cohort Event Monitoring
    • 13.3.5. EHR Mining
  • 13.4. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017-2027
    • 13.4.1. In-house
    • 13.4.2. Contract Outsourcing
  • 13.5. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Latin America Pharmacovigilance Market Attractiveness Analysis, 2021-2028
    • 13.6.1. By Phase of Drug Development
    • 13.6.2. By Type of Method
    • 13.6.3. By Type of Service
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Pharmacovigilance Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017-2027
    • 14.2.1. Preclinical Studies
    • 14.2.2. Phase I
    • 14.2.3. Phase II
    • 14.2.4. Phase III
    • 14.2.5. Phase IV or Post Marketing Surveillance
  • 14.3. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017-2027
    • 14.3.1. Spontaneous Reporting
    • 14.3.2. Intensified ADR Reporting
    • 14.3.3. Targeted Spontaneous Reporting
    • 14.3.4. Cohort Event Monitoring
    • 14.3.5. EHR Mining
  • 14.4. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017-2027
    • 14.4.1. In-house
    • 14.4.2. Contract Outsourcing
  • 14.5. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, 2021-2028
    • 14.6.1. By Phase of Drug Development
    • 14.6.2. By Type of Method
    • 14.6.3. By Type of Service
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share / Position Analysis, by Company, 2020
  • 15.3. Competitive Business Strategies
  • 15.4. Company Profiles
    • 15.4.1. Accenture plc
      • 15.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.1.2. Phase of Drug Development Portfolio
      • 15.4.1.3. Financial Overview
      • 15.4.1.4. Strategic Overview
      • 15.4.1.5. SWOT Analysis
    • 15.4.2. Bristol-Myers Squibb
      • 15.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.2.2. Phase of Drug Development Portfolio
      • 15.4.2.3. Financial Overview
      • 15.4.2.4. Strategic Overview
      • 15.4.2.5. SWOT Analysis
    • 15.4.3. Clinquest Group B.V.
      • 15.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.3.2. Phase of Drug Development Portfolio
      • 15.4.3.3. Financial Overview
      • 15.4.3.4. Strategic Overview
      • 15.4.3.5. SWOT Analysis
    • 15.4.4. Cognizant
      • 15.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.4.2. Phase of Drug Development Portfolio
      • 15.4.4.3. Financial Overview
      • 15.4.4.4. Strategic Overview
      • 15.4.4.5. SWOT Analysis
    • 15.4.5. Labcorp Drug Development
      • 15.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.5.2. Phase of Drug Development Portfolio
      • 15.4.5.3. Financial Overview
      • 15.4.5.4. Strategic Overview
      • 15.4.5.5. SWOT Analysis
    • 15.4.6. F. Hoffmann-La Roche Ltd.
      • 15.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.6.2. Phase of Drug Development Portfolio
      • 15.4.6.3. Financial Overview
      • 15.4.6.4. Strategic Overview
      • 15.4.6.5. SWOT Analysis
    • 15.4.7. GlaxoSmithKline plc
      • 15.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.7.2. Phase of Drug Development Portfolio
      • 15.4.7.3. Financial Overview
      • 15.4.7.4. Strategic Overview
      • 15.4.7.5. SWOT Analysis
    • 15.4.8. ICON plc
      • 15.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.8.2. Phase of Drug Development Portfolio
      • 15.4.8.3. Financial Overview
      • 15.4.8.4. Strategic Overview
      • 15.4.8.5. SWOT Analysis
    • 15.4.9. iGATE Corporation
      • 15.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.9.2. Phase of Drug Development Portfolio
      • 15.4.9.3. Financial Overview
      • 15.4.9.4. Strategic Overview
      • 15.4.9.5. SWOT Analysis
    • 15.4.10. iMEDGlobal Corporation
      • 15.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.10.2. Phase of Drug Development Portfolio
      • 15.4.10.3. Strategic Overview
      • 15.4.10.4. SWOT Analysis
    • 15.4.11. Syneos Health
      • 15.4.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.11.2. Phase of Drug Development Portfolio
      • 15.4.11.3. Financial Overview
      • 15.4.11.4. Strategic Overview
      • 15.4.11.5. SWOT Analysis
    • 15.4.12. Novartis AG
      • 15.4.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.12.2. Phase of Drug Development Portfolio
      • 15.4.12.3. Financial Overview
      • 15.4.12.4. Strategic Overview
      • 15.4.12.5. SWOT Analysis
    • 15.4.13. PAREXEL International Corporation
      • 15.4.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.13.2. Phase of Drug Development Portfolio
      • 15.4.13.3. Financial Overview
      • 15.4.13.4. Strategic Overview
      • 15.4.13.5. SWOT Analysis
    • 15.4.14. Pfizer, Inc.
      • 15.4.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.14.2. Phase of Drug Development Portfolio
      • 15.4.14.3. Financial Overview
      • 15.4.14.4. Strategic Overview
      • 15.4.14.5. SWOT Analysis
    • 15.4.15. Pharmaceutical Phase of Drug Development, LLC. (PPD)
      • 15.4.15.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.15.2. Phase of Drug Development Portfolio
      • 15.4.15.3. Financial Overview
      • 15.4.15.4. Strategic Overview
      • 15.4.15.5. SWOT Analysis
    • 15.4.16. IQVIA
      • 15.4.16.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.16.2. Phase of Drug Development Portfolio
      • 15.4.16.3. Financial Overview
      • 15.4.16.4. Strategic Overview
      • 15.4.16.5. SWOT Analysis
    • 15.4.17. Sanofi
      • 15.4.17.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.17.2. Phase of Drug Development Portfolio
      • 15.4.17.3. Financial Overview
      • 15.4.17.4. Strategic Overview
      • 15.4.17.5. SWOT Analysis
    • 15.4.18. Synowledge LLC
      • 15.4.18.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.18.2. Phase of Drug Development Portfolio
      • 15.4.18.3. Strategic Overview
      • 15.4.18.4. SWOT Analysis
    • 15.4.19. Wipro Limited
      • 15.4.19.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.4.19.2. Phase of Drug Development Portfolio
      • 15.4.19.3. Financial Overview
      • 15.4.19.4. Strategic Overview
      • 15.4.19.5. SWOT Analysis

List of Tables

  • Table 01: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017-2028
  • Table 02: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017-2028
  • Table 03: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017-2028
  • Table 04: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Region, 2017-2028
  • Table 05: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017-2028
  • Table 06: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017-2028
  • Table 07: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017-2028
  • Table 08: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Country, 2017-2028
  • Table 09: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017-2028
  • Table 10: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017-2028
  • Table 11: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017-2028
  • Table 12: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2028
  • Table 13: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017-2028
  • Table 14: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017-2028
  • Table 15: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017-2028
  • Table 16: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2028
  • Table 17: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017-2028
  • Table 18: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017-2028
  • Table 19: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017-2028
  • Table 20: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2028
  • Table 21: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017-2028
  • Table 22: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017-2028
  • Table 23: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017-2028
  • Table 24: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2028

List of Figures

  • Figure 01: Pharmacovigilance Market Snapshot
  • Figure 02: Global Pharmacovigilance Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2027
  • Figure 03: Market Value Share, by Phase of Drug Development, 2018
  • Figure 04: Market Value Share, by Type of Service, 2018
  • Figure 05: Market Value Share, by Region, 2018
  • Figure 06: Global Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
  • Figure 07: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Preclinical Studies, 2017-2028
  • Figure 08: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase I, 2017-2028
  • Figure 09: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase II, 2017-2028
  • Figure 10: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase III, 2017-2028
  • Figure 11: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase IV or Post Marketing Surveillance, 2017-2028
  • Figure 12: Global Pharmacovigilance Market Attractiveness Analysis, 2021-2028, by Phase of Drug Development
  • Figure 13: Global Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
  • Figure 14: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), Spontaneous Reporting, 2017-2028
  • Figure 15: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Intensified ADR Reporting, 2017-2028
  • Figure 16: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Targeted Spontaneous Reporting, 2017-2028
  • Figure 17: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cohort Event Monitoring, 2017-2028
  • Figure 18: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by EHR Mining, 2017-2028
  • Figure 19: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2028
  • Figure 20: Global Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
  • Figure 21: Global Pharmacovigilance Market Value Share Analysis, by Type of Service Providers, 2020 and 2028
  • Figure 22: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by In-house, 2017-2028
  • Figure 23: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Outsourcing, 2017-2028
  • Figure 24: Global Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
  • Figure 25: Global Pharmacovigilance Market Value Share Analysis, by Region, 2020 and 2028
  • Figure 26: Global Pharmacovigilance Market Attractiveness Analysis, by Region, 2021-2028
  • Figure 27: North America Pharmacovigilance Market Size (US$ Mn) Forecast, 2017-2028
  • Figure 28: North America Pharmacovigilance Market Attractiveness Analysis, by Country, 2021-2028
  • Figure 29: North America Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
  • Figure 30: North America Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
  • Figure 31: North America Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
  • Figure 32: North America Pharmacovigilance Market Value Share Analysis, by Country, 2020 and 2028
  • Figure 33: North America Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
  • Figure 34: North America Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
  • Figure 35: North America Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
  • Figure 36: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, 2017-2028
  • Figure 37: Europe Pharmacovigilance Market Attractiveness Analysis, by Country, 2021-2028
  • Figure 38: Europe Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
  • Figure 39: Europe Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
  • Figure 40: Europe Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
  • Figure 41: Europe Pharmacovigilance Market Value Share Analysis, by Country, 2020 and 2028
  • Figure 42: Europe Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
  • Figure 43: Europe Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
  • Figure 44: Europe Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
  • Figure 45: Asia Pacific Pharmacovigilance Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017- 2028
  • Figure 46: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Country 2021-2028
  • Figure 47: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
  • Figure 48: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
  • Figure 49: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
  • Figure 50: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Country, 2018 and 2027
  • Figure 51: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
  • Figure 52: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
  • Figure 53: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
  • Figure 54: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2028
  • Figure 55: Latin America Pharmacovigilance Market Attractiveness Analysis, 2021-2028, by Country/Sub-region, 2021-2028
  • Figure 56: Latin America Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
  • Figure 57: Latin America Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
  • Figure 58: Latin America Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
  • Figure 59: Latin America Pharmacovigilance Market Value Share Analysis, by Country/Sub-region, 2020 and 2028
  • Figure 60: Latin America Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
  • Figure 61: Latin America Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
  • Figure 62: Latin America Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
  • Figure 63: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, 2017-2028
  • Figure 64: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Country/Sub-region, 2021-2028
  • Figure 65: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
  • Figure 66: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
  • Figure 67: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
  • Figure 68: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Country/Sub-region, 2020 and 2028
  • Figure 69: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
  • Figure 70: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
  • Figure 71: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
  • Figure 72: Global Pharmacovigilance Market Share Analysis, by Company (2020)